Samsung Biologics, the South Korean contract development and manufacturing organisation (CDMO), saw its shares slide more than 4% in Monday trading on the Korea Exchange after the company issued a weaker-than-expected earnings forecast for the third quarter. The decline marks the stock's biggest single-day drop in three months and has dragged down other biopharma stocks across Asia.
The company attributed the downgrade to a slower pipeline of new contract wins and intensifying competition from Chinese and European rivals. Samsung Biologics, which counts major global pharmaceutical firms among its clients, had previously enjoyed a strong run on the back of pandemic-era vaccine and antibody production deals. Analysts now warn that the post-pandemic normalisation is squeezing margins across the sector.
In London, the FTSE 100 edged 0.2% lower to 8,215 points in early afternoon trade, with the health care sector giving up 0.5%. Shares of AstraZeneca dipped 0.3%, while contract research firm IQVIA — though US-listed — saw its UK-listed depositary receipts fall. The FTSE 250 was broadly flat at 20,940.
“The Samsung Biologics news is a reminder that the CDMO boom is cooling,” said an analyst at a London-based investment bank, speaking on condition of anonymity. “UK investors with exposure to global pharma supply chains should watch for further guidance cuts, though the long-term structural story remains intact.”
For UK pension and ISA holders, the sell-off underscores the vulnerability of international biotech holdings to shifts in manufacturing demand. While the direct exposure to Samsung Biologics in UK portfolios is limited, the ripple effects on global health care indices could affect tracker funds and multi-asset pensions.